Neuralink

Type: Company (Brain-Computer Interface)

Neuralink is the most visible and well-funded player in invasive brain-computer interfaces. The company's N1 implant — a coin-sized device with 1,024 electrodes inserted into the motor cortex — enables thought-controlled computing for patients with paralysis.

The PRIME (Precise Robotically Implanted Brain-Computer Interface) study has implanted approximately 20 patients as of early 2026, demonstrating cursor control, typing, and gaming through neural signals. The FDA granted breakthrough device designation, and the company has announced international expansion with clinical trials in the UK and UAE.

Neuralink's approach is maximally invasive (intracortical electrode array requiring craniotomy) but achieves the highest signal quality of any commercial BCI. The surgical robot that performs the implantation is itself a significant engineering achievement — precision placement of flexible electrodes into brain tissue at scale requires robotic accuracy beyond human surgical capability.

The company's long-term vision extends beyond medical restoration to neural augmentation — enhancing human cognitive capabilities through brain-computer symbiosis. This remains speculative and raises significant ethical questions, but the medical restoration pathway provides a viable commercial and regulatory entry point.

Key Contributions

• PRIME study: ~20 patients with thought-controlled computing (Neuralink PRIME)
• FDA breakthrough device designation for N1 implant (Neuralink PRIME)
• International expansion: UK and UAE clinical trials (Neuralink PRIME)
• 1,024-electrode intracortical array with robotic surgical insertion (Neuralink PRIME)

Mentioned In

• Invasive vs. Non-Invasive BCI — Primary example of invasive BCI
• Neuroprosthetics — Motor function restoration clinical leader
• Neural Signal Decoding — High-bandwidth signal source for decoding

Related Entities

• Synchron — Minimally invasive competitor